ポイントオブケア分子診断市場：製品、技術、用途、エンドユーザー別-2025-2030年の世界予測

ポイントオブケア分子診断市場は、2023年に27億米ドルと評価され、2024年には29億5,000万米ドルに達すると予測され、CAGR 9.65％で成長し、2030年には51億5,000万米ドルに達すると予測されています。

ポイント・オブ・ケア（POC）分子診断の範囲には、迅速で局所的な検査が含まれ、即座の意思決定を可能にし、特に集中検査施設へのアクセスが限られている環境において、重要なヘルスケア上のメリットを提供します。これらの診断法は、感染症や遺伝性疾患の検出、様々な健康状態のモニタリングに不可欠であり、検査から結果までの所要時間を短縮し、患者のケアを向上させる。主な用途は、感染症検出、腫瘍学、出生前検査、薬理ゲノミクスです。主なエンドユーザーには、病院、診療所、在宅ケア環境、外来サービスなどがあります。市場成長の主な原動力は、疾患の早期発見や個別化医療に対する需要の増加、マイクロ流体技術や小型化などの技術進歩、感染症やがん・性感染症などの健康問題の有病率の上昇です。パンデミックは、COVID-19のようなウイルス性疾患に対する迅速で正確なPOC検査の需要をさらに加速させています。しかし、課題としては、高度なPOC技術に関連する高コスト、規制の複雑さ、これらの診断ツールを操作する訓練を受けたヘルスケア人材の限られた利用可能性などがあります。潜在的なビジネスチャンスは、低コストで高効率のポータブル機器の開発と、慢性疾患管理や希少遺伝子疾患への応用拡大にあります。手頃な価格を損なうことなく、検査精度と速度を向上させるための研究開発への投資は、極めて重要です。人工知能と機械学習をPOC診断に統合し、予測分析能力を強化することに重点を置いたイノベーションも可能です。企業は、消費者ニーズの進化を先取りしてイノベーションを推進し、競争優位性を維持するために、テクノロジー企業との提携を模索するかもしれないです。課題はあるもの、POC分子診断市場は大きな潜在力を秘めており、コストとアクセスの問題に対処するイノベーションが持続的成長の主な道筋となります。

市場力学：急速に進化するポイントオブケア分子診断市場の主要市場インサイトを公開

ポイントオブケア分子診断市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 感染症、院内感染（HAI）、がんの有病率の増加
  • 高度な治療・診断選択肢に対する認識と受容の高まり
  • 在宅ヘルスケアにおける分子診断の急速な普及
• 市場抑制要因
  • 不十分な償還シナリオ
• 市場機会
  • 診断の手頃さを提供するアレルギー診断のためのmヘルス人気の高まり
  • DNAシーケンシングと解析の技術的進歩
• 市場の課題
  • 厳しく時間のかかる規制政策

ポーターの5つの力：ポイントオブケア分子診断市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ポイントオブケア分子診断市場における外部からの影響の把握

外部マクロ環境要因は、ポイントオブケア分子診断市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ポイントオブケア分子診断市場における競合情勢の把握

ポイントオブケア分子診断市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスポイントオブケア分子診断市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ポイントオブケア分子診断市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ポイントオブケア分子診断市場における成功への道筋を描く

ポイントオブケア分子診断市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 感染症、院内感染（HAI）、がんの蔓延の増加
    • 先進的な治療法や診断法に対する認識と受容の高まり
    • 在宅ヘルスケアにおける分子診断の迅速な利用
  • 抑制要因
    • 不十分な償還シナリオ
  • 機会
    • 手頃な価格で診断が受けられるアレルギー診断のためのmヘルスの人気が高まっている
    • DNA配列解析と分析における技術的進歩
  • 課題
    • 厳格で時間のかかる規制政策
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ポイントオブケア分子診断市場：製品別

• アナライザー
• キットとアッセイ
• ソフトウェアとサービス

第7章 ポイントオブケア分子診断市場：技術別

• 等温核酸増幅技術
• リアルタイムポリメラーゼ連鎖反応

第8章 ポイントオブケア分子診断市場：用途別

• 院内感染
• 新生児検査
• 腫瘍学
• 呼吸器疾患
• 性感染症

第9章 ポイントオブケア分子診断市場：エンドユーザー別

• クリニックおよび診断研究所
• 病院の外来部門と集中治療室
• 調査・学術機関

第10章 南北アメリカのポイントオブケア分子診断市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のポイントオブケア分子診断市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのポイントオブケア分子診断市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• ACON LABS INC.
• Becton, Dickinson and Company
• Binx Health, inc.
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Cardinal Health, Inc.
• Chembio Diagnostics Inc.
• Co-Diagnostics, Inc.
• Danaher Corporation
• DiaSorin S.p.A
• EKF Diagnostics Holdings
• FHoffmann-La Roche AG
• Genomadix Inc.
• Grifols, S.A
• Henry Schein, Inc.
• Johnson & Johnson Services, Inc.
• Novartis AG
• OraSure Technologies, Inc.
• Pfizer, Inc.
• QIAGEN N.V.
• Quidel Corporation
• SD Biosensor
• Sekisui Diagnostics
• SHUWEN BIOTECH CO., LTD
• Siemens Healthineers AG
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAL-TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL ACQUIRED INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEONATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL OUTPATIENT DEPARTMENTS & INTENSIVE CARE UNITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 39. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 61. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 65. INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 133. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 134. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. POLAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 149. POLAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 150. POLAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 151. POLAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 152. QATAR POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 153. QATAR POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 154. QATAR POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. QATAR POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 192. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 193. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Point of Care Molecular Diagnostics Market was valued at USD 2.70 billion in 2023, expected to reach USD 2.95 billion in 2024, and is projected to grow at a CAGR of 9.65%, to USD 5.15 billion by 2030.

The scope of Point of Care (POC) Molecular Diagnostics involves rapid, localized testing that enables immediate decision-making, providing crucial healthcare benefits, especially in settings with limited access to centralized laboratory facilities. These diagnostics are essential in detecting infectious diseases, genetic disorders, and monitoring various health conditions, offering faster test-to-result turnaround times and enhancing patient care. The main applications are in infectious disease detection, oncology, prenatal testing, and pharmacogenomics. Key end-users include hospitals, clinics, home care settings, and ambulatory services. Market growth is chiefly driven by increasing demand for early disease detection and personalized medicine, technological advancements like microfluidics and miniaturization, and the rising prevalence of infectious diseases and health issues such as cancer and sexually transmitted infections. The pandemic has further accelerated the demand for rapid and accurate POC testing for viral diseases such as COVID-19. However, challenges include high costs associated with advanced POC technologies, regulatory complexities, and the limited availability of trained healthcare personnel to operate these diagnostic tools. Potential opportunities lie in the development of low-cost, high-efficiency portable devices and expanding applications into chronic disease management and rare genetic disorders. Investment in R&D to improve assay accuracy and speed without compromising affordability could be pivotal. Innovations can focus on integrating artificial intelligence and machine learning into POC diagnostics to enhance predictive analytics capabilities. Businesses might explore partnerships with technology firms to drive innovation and maintain competitive advantage by staying ahead of evolving consumer needs. Despite the challenges, the POC molecular diagnostics market holds significant potential, with innovations addressing pains of cost and access being the primary path for sustained growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Point of Care Molecular Diagnostics Market

The Point of Care Molecular Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of infectious diseases, hospital acquired infections (HAIs), and cancer
  • Growing awareness and acceptance of advanced therapeutic and diagnostic choices
  • Rapid use of molecular diagnostics for home healthcare
• Market Restraints
  • Inadequate reimbursement scenario
• Market Opportunities
  • Growing popularity of mHealth for allergy diagnosis offering the affordability of diagnosis
  • Technological advancements in DNA sequencing and analysis
• Market Challenges
  • Stringent and time-consuming regulatory policies

Porter's Five Forces: A Strategic Tool for Navigating the Point of Care Molecular Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Point of Care Molecular Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Point of Care Molecular Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Point of Care Molecular Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Point of Care Molecular Diagnostics Market

A detailed market share analysis in the Point of Care Molecular Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Point of Care Molecular Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Point of Care Molecular Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Point of Care Molecular Diagnostics Market

A strategic analysis of the Point of Care Molecular Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Point of Care Molecular Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ACON LABS INC., Becton, Dickinson and Company, Binx Health, inc., Bio-Rad Laboratories, Inc., bioMerieux SA, Cardinal Health, Inc., Chembio Diagnostics Inc., Co-Diagnostics, Inc., Danaher Corporation, DiaSorin S.p.A, EKF Diagnostics Holdings, FHoffmann-La Roche AG, Genomadix Inc., Grifols, S.A, Henry Schein, Inc., Johnson & Johnson Services, Inc., Novartis AG, OraSure Technologies, Inc., Pfizer, Inc., QIAGEN N.V., Quidel Corporation, SD Biosensor, Sekisui Diagnostics, SHUWEN BIOTECH CO., LTD, Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Point of Care Molecular Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Analyzers, Kits & Assays, and Software & Services.
• Based on Technology, market is studied across Isothermal Nucleic Acid Amplification Technology and Real-Time Polymerase Chain Reaction.
• Based on Application, market is studied across Hospital Acquired Infections, Neonatal Testing, Oncology, Respiratory Diseases, and Sexually Transmitted Diseases.
• Based on End-User, market is studied across Clinics & Diagnostic Laboratories, Hospital Outpatient Departments & Intensive Care Units, and Research & Academic Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of infectious diseases, hospital acquired infections (HAIs), and cancer
    • 5.1.1.2. Growing awareness and acceptance of advanced therapeutic and diagnostic choices
    • 5.1.1.3. Rapid use of molecular diagnostics for home healthcare
  • 5.1.2. Restraints
    • 5.1.2.1. Inadequate reimbursement scenario
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing popularity of mHealth for allergy diagnosis offering the affordability of diagnosis
    • 5.1.3.2. Technological advancements in DNA sequencing and analysis
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent and time-consuming regulatory policies
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Point of Care Molecular Diagnostics Market, by Product

• 6.1. Introduction
• 6.2. Analyzers
• 6.3. Kits & Assays
• 6.4. Software & Services

7. Point of Care Molecular Diagnostics Market, by Technology

• 7.1. Introduction
• 7.2. Isothermal Nucleic Acid Amplification Technology
• 7.3. Real-Time Polymerase Chain Reaction

8. Point of Care Molecular Diagnostics Market, by Application

• 8.1. Introduction
• 8.2. Hospital Acquired Infections
• 8.3. Neonatal Testing
• 8.4. Oncology
• 8.5. Respiratory Diseases
• 8.6. Sexually Transmitted Diseases

9. Point of Care Molecular Diagnostics Market, by End-User

• 9.1. Introduction
• 9.2. Clinics & Diagnostic Laboratories
• 9.3. Hospital Outpatient Departments & Intensive Care Units
• 9.4. Research & Academic Institutes

10. Americas Point of Care Molecular Diagnostics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Point of Care Molecular Diagnostics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Point of Care Molecular Diagnostics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. ACON LABS INC.
• 3. Becton, Dickinson and Company
• 4. Binx Health, inc.
• 5. Bio-Rad Laboratories, Inc.
• 6. bioMerieux SA
• 7. Cardinal Health, Inc.
• 8. Chembio Diagnostics Inc.
• 9. Co-Diagnostics, Inc.
• 10. Danaher Corporation
• 11. DiaSorin S.p.A
• 12. EKF Diagnostics Holdings
• 13. FHoffmann-La Roche AG
• 14. Genomadix Inc.
• 15. Grifols, S.A
• 16. Henry Schein, Inc.
• 17. Johnson & Johnson Services, Inc.
• 18. Novartis AG
• 19. OraSure Technologies, Inc.
• 20. Pfizer, Inc.
• 21. QIAGEN N.V.
• 22. Quidel Corporation
• 23. SD Biosensor
• 24. Sekisui Diagnostics
• 25. SHUWEN BIOTECH CO., LTD
• 26. Siemens Healthineers AG
• 27. Sysmex Corporation
• 28. Thermo Fisher Scientific Inc.